CLINICAL TRIALS PROFILE FOR ERYTHROMYCIN LACTOBIONATE
✉ Email this page to a colleague
All Clinical Trials for erythromycin lactobionate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00034736 ↗ | A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2002-08-01 | The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia. |
NCT02605122 ↗ | Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia | Terminated | Biomedical Advanced Research and Development Authority | Phase 2/Phase 3 | 2016-04-01 | This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP). |
NCT02605122 ↗ | Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia | Terminated | Cempra Inc | Phase 2/Phase 3 | 2016-04-01 | This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP). |
NCT02605122 ↗ | Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia | Terminated | Melinta Therapeutics, Inc. | Phase 2/Phase 3 | 2016-04-01 | This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP). |
NCT02633579 ↗ | Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways | Completed | Universitaire Ziekenhuizen Leuven | N/A | 2012-10-01 | In this study, the investigators will evaluate if the food intake associated with the infusion of erythromycin is caused by the phase 3 contractions or by another yet unknown effect of erythromycin. To obtain this the investigators will use atropine, a muscarinic receptor antagonist, to inhibit the formation of contractions induced by a low dose of erythromycin |
NCT02755064 ↗ | Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus | Completed | Adil Bharucha | Phase 1 | 2010-06-01 | With this study, the investigators hoped to learn if the rate at which food empties from the stomach affects blood sugar values. Using data from this study, we hope to improve our ability to control blood sugars in individuals with type 1 diabetes mellitus. |
NCT04066231 ↗ | ANTERO-4: VIPUN Gastric Monitoring System in an Erythromycin Model | Terminated | Prof Dr Jan Tack | N/A | 2019-09-07 | It has been demonstrated that the VIPUN Gastric Monitoring System (GMS) can discriminate healthy physiological and pharmacologically-inhibited gastric motility, using a codeine-model in healthy adults (S60320 / AFMPS80M0687). Erythromycin is a gastroprokinetic agent, known to stimulate gastric contractility. A single dose of 200 mg erythromycin has been shown to induce a prolonged period of enhanced phasic contractile activity. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults. The performance of the VIPUN GMS can be enhanced by data-driven optimization of the VIPUN Motility Algorithm, used to quantify gastric motility. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for erythromycin lactobionate
Condition Name
Clinical Trial Locations for erythromycin lactobionate
Trials by Country
Clinical Trial Progress for erythromycin lactobionate
Clinical Trial Phase
Clinical Trial Sponsors for erythromycin lactobionate
Sponsor Name